Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 14/20 | 0.53 |
| ▸ | SYK | P43405 | 5/20 | 0.38 |
| ▸ | SRC | P12931 | 4/20 | 0.38 |
| ▸ | ZAP70 | P43403 | 4/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5551914 | 0.96 | CRHR1 (0.54) | CRHR1SYKSRCZAP70CDK2 | |
| SCHEMBL3241949 | 0.88 | CRHR1 (0.49) | CRHR1SYKSRCZAP70 | |
| SCHEMBL5547372 | 0.87 | CRHR1 (0.49) | CRHR1SYKSRCZAP70PDE10A | |
| SCHEMBL5550003 | 0.86 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL5572320 | 0.84 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL5568075 | 0.81 | CRHR1 (0.50) | CRHR1SYKSRCZAP70 | |
| SCHEMBL5572074 | 0.81 | CRHR1 (0.47) | CRHR1SYKSRCPDE10A | |
| SCHEMBL5547345 | 0.79 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL5572212 | 0.78 | CRHR1 (0.45) | CRHR1PDE10A | |
| SCHEMBL5550638 | 0.77 | CRHR1 (0.57) | CRHR1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1695974-B1 | 1,8-Naphthyridines as CRF antagonists | GLAXO GROUP LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-20070219232-A1 | Chemical Compounds | GLAXO GROUP LIMITED | 2007-09-20 | — | — | US | disclosed |
| US-7253284-B2 | Chemical compounds | GIAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1695974-A1 | 1,8-Naphthyridines as CRF antagonists | GLAXO GROUP LIMITED (GB) | 2006-08-30 | — | — | EP | disclosed |
| US-20040171607-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171607-A1 | Chemical compounds | CBR3, CBR1, CYP2B6 | CRHR1 52/4885SYK 4534/4885SRC 2470/4885 |
| US-20070219232-A1 | Chemical Compounds | CBR3, CBR1, HCAR3 | CRHR1 30/4885SYK 4288/4885SRC 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.